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http://dx.doi.org/10.1016/j.ccell.2015.04.005SUMMARYChoroid plexus carcinomas (CPCs) are poorly understood and frequently lethal brain tumors with few treat-
ment options. Using amousemodel of the disease and a large cohort of human CPCs, we performed a cross-
species, genome-wide search for oncogenes within syntenic regions of chromosome gain. TAF12, NFYC,
and RAD54L co-located on human chromosome 1p32-35.3 and mouse chromosome 4qD1-D3 were identi-
fied as oncogenes that are gained in tumors in both species and required for disease initiation and progres-
sion. TAF12 andNFYC are transcription factors that regulate the epigenome,whereasRAD54L plays a central
role in DNA repair. Our data identify a group of concurrently gained oncogenes that cooperate in the forma-
tion of CPC and reveal potential avenues for therapy.INTRODUCTION
Various genetic alterations activate oncogenes or delete tumor
suppressor genes (TSGs) in cancer. Recurrent mutations that
disrupt the same gene can be highly informative, pinpointing
oncogenic alterations that may serve as therapeutic targets
(Baselga et al., 1996; Druker et al., 2001; Flaherty et al., 2010).
However, focal alterations are relatively infrequent in many can-
cers, particularly those arising in children (Alexandrov et al.,
2013; Zhang et al., 2012). Rather, these tumors contain large
DNA copy number alterations (CNAs) that presumably drive
the overexpression of oncogenes or delete TSGs (Chen et al.,
2014; Downing et al., 2012; Johnson et al., 2010; Wu et al.,
2012). These CNAs are often chromosomal in scale, making it
difficult to identify which genes are driving transformation. RNASignificance
Few recurrent point mutations or focal amplifications have bee
cancers. Rather, these tumors contain large chromosomal alter
the identification of oncogenes difficult. Choroid plexus carc
2,100 genes. Using a combination of cross-species genomics
ment of chromosome 1p that is gained early in mouse CPC dev
andRad54l—required to initiate and progress the disease. This
regions of chromosomal gain and the associated dysregulated
712 Cancer Cell 27, 712–727, May 11, 2015 ª2015 Elsevier Inc.silencing technologies have discovered TSGs within large
deletions (Scuoppo et al., 2012; Xue et al., 2012; Zender et al.,
2008); but approaches to screen the oncogenic capacity
of genes located within large regions of gain are less well
developed.
Choroid plexus carcinomas (CPCs) are highly malignant brain
tumors that are characterized by gains of chromosomes 1, 2, 4,
7, 12, 14, 19, 20, and 21, and numerous autosomal losses (Pau-
lus and Brandner, 2007; Rickert et al., 2002; Ruland et al., 2014).
The great majority of CPCs are diagnosed in children aged less
than 3 years, two-thirds of whom die within 5 years (Wrede
et al., 2009). Efforts to identify more effective treatments of
CPC have been hindered by poor understanding of its pathogen-
esis. Germline alterations of TP53, and possibly hSNF5/INI1,
predispose to CPC in humans (Garber et al., 1991; Malkinn identified in whole genome sequencing studies of pediatric
ations encompassing tens to thousands of genes, rendering
inomas (CPC) frequently gain chromosome 1 that encodes
and in vivo functional studies, we identified a syntenic frag-
elopment, and that contains three oncogenes—Taf12, Nfyc,
approach holds promise to pinpoint oncogenes within large
pathways that might serve as therapeutic targets.
et al., 1990; Olivier et al., 2003; Se´e´venet et al., 1999; Tinat et al.,
2009) and ablation of Tp53 and/or Rb function causes CPCs in
mice (Brinster et al., 1984; Sa´enz Robles et al., 1994). Deletion
of PTEN has also been implicated in CPC, but the oncogenes
that drive this cancer have not been identified (Morigaki et al.,
2012; Rickert et al., 2002; Ruland et al., 2014). The goal of our
study was to identify CPC oncogenes within large regions of
chromosome gain.
RESULTS
Tp53, Rb, and Pten Suppress CPC
To better understand the cellular andmolecular origin of CPC,we
first developed a mouse model of the disease (Figure 1). Using in
utero electroporation, we introduced Cre Recombinase into the
hindbrain choroid plexus epithelium (CPE) of embryonic day (E)
12.5 mice carrying various conditional alleles. At postnatal day
(P) 0, efficient recombination was evident in the CPE of mice car-
rying the ROSA-yellow fluorescence protein (ROSAYFP) lineage
tracing allele (Figures 1A and 1B). YFP+ CPE cells expressing
Transthyretin (Ttr), a marker of mature CPE (Harms et al., 1991),
were retained by adult RosaYFP mice that had been electropo-
rated in uterowithCreRecombinase; but thesemice never devel-
oped tumors (total mice n = 7, Figures 1C–1E). In stark contrast,
electroporation of Cre Recombinase into the hindbrain CPE of
Tp53flx/flx; Rbflx/flx; Ptenflx/flx; ROSAYFP E12.5 embryos resulted
in CPCs within 220 days of postnatal life (penetrance, 38% [n =
26/69]; Figures 1F–1O). All tumors were YFP+, confirming their
origin from in utero Cre-recombined cells (Figures 1F and 1G).
Mouse CPCs recapitulated the morphology (admixed papillary
and syncytial architecture and pleomorphic epithelioid cytology
[Figure 1H]); differentiation state (relative decrease in Ttr
expression and expression of cytokeratin 8 [Figures 1I and 1J]);
proliferation (high Ki67 and BrDU labeling index [Figure 1K]),
and ultrastructural features (microvilli, intracellular tight junc-
tions, and extensive basal membrane folding [Figures 1L and
1M]) of the humandisease. Allele specific polymerase chain reac-
tions confirmed the deletion of Tp53, Rb, and Pten from these
tumors but not adjacent normal tissue (Figure 1N).
Tp53 and Rb, but not Pten, have previously been shown to
suppress CPC (Brinster et al., 1984; Sa´enz Robles et al., 1994).
Therefore, to better assess the role of Pten as a CPC TSG, we
performed tumor surveillance studies of Tp53flx/flx; Rbflx/flx;
ROSAYFP (n = 68), Tp53flx;flx; Ptenflx/flx; ROSAYFP (n = 36) and
Rbflx;flx; Ptenflx/flx; ROSAYFP (n = 24) mice electroporated with
Cre Recombinase at E12.5. Only 10% (n = 7/68) of Tp53flx/flx;
Rbflx/flx; ROSAYFP and no Tp53flx;flx; Ptenflx/flx; ROSAYFP or
Rbflx;flx; Ptenflx/flx; ROSAYFP mice developed CPCs (Figure 1O).
Thus, in our model, loss of both Tp53 and Rb is required to
generate CPC, and neither of these deletions can be substituted
by loss of Pten. However, deletion of Pten together with loss of
Tp53 and Rb significantly increases tumor penetrance.
To further characterize our model, we compared the gene
expression profiles of Tp53flx/flx; Rbflx/flx; Ptenflx/flx; ROSAYFP
CPCs with those of other mouse hindbrain tumors and tissues
(Figure 1P). The transcriptomes of CPC and normal adult and
embryonic choroid plexuses co-clustered separately from
those of medulloblastoma and normal embryonic and/or adult
brainstem and cerebellum (Gibson et al., 2010; Uziel et al.,2005). Furthermore, gene set enrichment analysis (GSEA) iden-
tified ‘‘Markers of Choroid Plexus’’ as the most enriched of
4,293 gene sets in CPCs relative to mouse medulloblastoma,
brainstem and cerebellum (Figure 1Q; Table S1). Among the
choroid plexus derived tissues, CPCs were more closely related
to embryonic than adult choroid. Thus our mouse CPCs reca-
pitulate the histological and ultrastructural features of the hu-
man disease and express an embryonic choroid plexus-like
transcriptome.
Chromosome 1p31.3-ter Encodes Candidate CPC
Oncogenes
To identify genetic alterations that drive CPC,we used Affymetrix
6.0 DNA SNP microarrays to catalog CNAs in human choroid
plexus papillomas (CPPs, n = 32) and human CPCs (n = 23; Table
S2). We also performed microarray comparative genomic hy-
bridization (aCGH) of 47 Tp53flx/flx; Rbflx/flx; Ptenflx/flx; ROSAYFP
mouse CPCs, including 12 primary tumors and serial secondary
(n = 20) and tertiary (n = 15) orthotopic transplants of these tu-
mors. Additionally, we sequenced the whole genomes (WGS)
of four human CPCs andmatched normal blood (>98% of the tu-
mor genome and >91% of the normal genome had 20-fold
coverage with high-quality sequence reads; see Supplemental
Experimental Procedures). No recurrent, single nucleotide varia-
tions, insertion/deletions, or focal CNAs (less than 5 genes) were
identified in the four human CPCs subject to WGS, although one
of these cases had extensive chromothripsis of chromosomes 1
and 19 in the absence of a mutation in TP53 (Tables S3, S4, S5,
S6, and S7; Supplemental Experimental Procedures). However,
as expected, human CPCs contained numerous, recurrent,
chromosomal gains and losses (Figure 2A). Similar non-random
chromosomal alterations were observed in mouse tumors, sug-
gesting large CNAs are a primary oncogenic driver of CPC
(Figure 2B).
Because both human and mouse CPCs contained recurrent
chromosomal CNAs, we looked for syntenic chromosome
fragments that were gained in tumors in both species since
these might be enriched for oncogenes. Whereas 61% (n =
14/23) of human CPCs gained at least one whole copy
of chromosome 1 (encoding 2,100 genes), only one syntenic
fragment of chromosome 1 was gained in mouse CPCs (encod-
ing 671 genes; mouse chromosome 4qC6-qE2 [94,608,732-
155,608,945]; syntenic with human chromosome 1p31.3-ter
[895,967- 67,594,220]; Figure 2C). Gain of 4qC6-qE2 was seen
in 50% (n = 6/12) of mouse CPCs and was retained through
secondary and tertiary serial tumor transplants (Figure 2C).
Only 3% (n = 1/32) of themore benign human CPPs gained chro-
mosome 1. Thus human chromosome 1p31.3-ter / mouse chro-
mosome 4qC6-qE2 (hereon, chr1p31.3-ter/4qC6-qE2) may
harbor oncogenes that drive aggressive choroid plexus tumors.
Notably, gain of chr1p31.3-ter/4qC6-qE2 may be associated
with dysfunctional TP53 since our mouse model is Tp53 null
and chromosome 1 gain was significantly associated with
mutant TP53 in human CPCs (Fisher’s Exact, p < 0.05; Figure 3;
Table S2). Similar analyses of other autosomal gains in human
CPCs including chromosomes 7 and 12 that are among the
most commonly gained chromosomes in the disease (Rickert
et al., 2002), failed to identify additional syntenic gains (Figures
2D and 2E).Cancer Cell 27, 712–727, May 11, 2015 ª2015 Elsevier Inc. 713
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To further resolve which of the 671 genes on chr1p31.3-ter/
4qC6-qE2 might be oncogenes, we integrated the copy
number and expression of this region in human and mouse
tumors to identify genes that were both gained and overex-
pressed (Figure 3). Twenty-six percent of genes (n = 176/671)
on human chromosome 1p31.3-ter were significantly overex-
pressed in human tumors that gained this region (n = 9), relative
to those in which it was balanced or deleted (tumors, n = 25;
log ratio R 2, p < 0.05 with Bonferonni correction). Mouse
CPCs that gained 4qC6-qE2 (n = 15) overexpressed 11% of
genes (n = 64/579 Affymetrix 430 microarray) in this region rela-
tive to balanced mouse tumors (n = 5) and normal mouse
choroid plexus (n = 7; log ratio R 2, p < 0.05 with Bonferonni
correction). Comparison of these human and mouse data re-
vealed a common set of 21 genes on chr1p31.3-ter/4qC6-
qE2 that were both gained and overexpressed in human and
mouse CPCs, pinpointing these as ‘‘lead candidate’’ onco-
genes (Figure 3).
Gain of Chromosome 4qC6-qE2 Is an Early Event in CPC
Tumorigenesis
Cancers accumulate genetic alterations sequentially, suggesting
these defects play temporally distinct roles during transforma-
tion. Therefore, to enable appropriate investigation of our 21
lead candidate oncogenes, we first determined when 4qC6-
qE2 is gained during mouse CPC development (Figure 4).
Tp53flx/flx; Rbflx/flx; Ptenflx/flx; ROSAYFP mice were electroporated
in uterowith Cre Recombinase exactly as described above.Mice
were then killed at P0, P21, or P35 two hours following injection
with BrdU and their hindbrains subject to histologic study (four or
more mice per time point).
One week following electroporation (P0), small areas of
dysplastic YFP+ CPE were visible in which the epithelium lost
its monolayer organization and decreased its expression of Ttr.
However, significant proliferation (BrdU incorporation), DNA
double strand breaks (DSB; gH2ax staining) and gain of 4qC6-
qE2 (fluorescence in situ hybridization [FISH]) were not detected
(Figures 4A–4D). Three weeks later (P21), the amount of
dysplastic YFP+/Ttr CPE had clearly increased and significant
numbers of aberrantly proliferating YFP+/BrdU+ CPE were now
detected relative to control mice (p < 0.05 Mann-Whitney; Fig-
ures 4A and 4B); however, neither DNA double stand breaks
nor 4qC6-qE2 gain were apparent. By 6 weeks post-electropo-
ration (P35), the choroid plexus had undergone a dramatic
change: large regions of hyperplastic CPE were now visible, in
which 20% ± 2.4SE of YFP+ CPE were proliferating (BrdU+, p <Figure 1. A Mouse Model of CPC
(A and B) Expression of the recombined ROSAYFP fluorescent lineage tracing allel
choroid plexus following in utero electroporation with Cre-recombinase at embry
(C–E) Recombined (C), but histologically normal (D) and Ttr+ (E) choroid plexus p
(F–M) In utero electroporation of the hindbrain choroid plexus of Tp53flx/flx;Rbflx/flx;
recapitulate the histology (H); reduced Ttr (I) and increased Cytokeratin 8 (J) expre
CPC (scale bar in F–K represents 20 mm; L and M, 2 mm).
(N) Polymerase chain reactions of recombined (RC) alleles in mouse CPC (T) and
(O) Kaplan-Meier survival curves of E12.5 mice harboring the indicate alleles tha
(P) Unsupervised hierarchical clustering of gene expression profiles of mouse: C
medulloblastomas; P7 dorsal brainstem (P7 DBS); P7 cerebellum (P7 CB); E12.5
(Q) GSEA of ‘‘Lein choroid plexus markers’’ in CPC reporting normalized enrichm
See also Table S1.0.0005 Mann Whitney, relative to controls; Figures 4A and 4B).
In addition, significant DNA DSBs and gain of 4qC6-qE2 were
now detected in YFP+ CPE (both p < 0.05, Mann-Whitney; Fig-
ures 4A, 4C, and 4D). Interestingly, while high levels of aberrant
proliferation and gain of 4qC6-qE2 persisted in fully formed
CPCs, DSBs were not detected in tumors (Figures 4B–4D).
Together, these data confirm that mouse CPCs develop from
mutated CPE and that gain of 4qC6-qE2 is a relatively early event
in the disease process, coinciding with choroid plexus hyperpla-
sia and suggesting this region may contain oncogenes that play
a role in tumor initiation.
Taf12, Nfyc and Rad54l Promote Aberrant Proliferation
of the Developing Choroid Plexus
Because gain of 4qC6-qE2 is an early event in CPC develop-
ment, we reasoned that developing choroid plexus would be
an appropriate context in which to screen the transforming po-
tential of our 21 lead candidate oncogenes. To do this, we tested
the capacity of each candidate to drive dysplasia and prolifera-
tion of early postnatal CPE that is normally a single layer of
post-mitotic cuboidal epithelium (Lehtinen et al., 2013). Plasmids
expressing green fluorescence protein (GFP) and a single lead
candidate oncogene each were co-electroporated into the hind-
brain CPE of separate cohorts of E12.5 embryos (five or more
embryos/candidate, total n = 107 embryos; Figure 5A). Prolifer-
ating CPE cells were labeled at E19.5 by maternal injection of
BrdU. The proportion of targeted and proliferating (GFP+/
BrdU+), relative to targeted but non-proliferating (GFP+/BrdU),
CPE cells was calculated at P0. Five control mice were electro-
porated with empty vector-GFP.
GFP+ cells were detected in all electroporated mice. Fewer
than 0.5% of electroporated (GFP+) CPE cells were proliferating
(BrdU+) in embryos that were electroporated with control
plasmid or 13 of 21 lead candidate oncogenes (Figures 5A–
5C). Expression of five other candidates (Cdc20, Stmn1,
Atp6v0b, Clspn, and Mier1) was associated with proliferation in
0.5%–2% of GFP+ cells but did not alter choroid plexus
morphology (Figures 5B and 5C). In marked contrast, Taf12,
Nfyc, andRad54l inducedCPEdysplasia and proliferation similar
to that observed following 4qC6-qE2 gain in Cre-electroporated
Tp53flx/flx; Rbflx/flx; Ptenflx/flx; ROSAYFPmice (compare Figures 4A
and 5B). Both Taf12 (23.2% ± 8.4SE BrdU+YFP+, p < 0.005
Mann-Whitney) and Nfyc (4.0% ± 2.0SE BrdU+YFP+, p < 0.05
Mann-Whitney) induced significant levels of CPE proliferation
relative to control transduced cells. Notably, we observed a
worse prognosis among patients whose CPCs expressede in whole (A) and microscopic (B) preparations of postnatal day (P) 0 hindbrain
onic day (E) 12.5 (scale bar represents 50 mm).
ersisting in adult CPE (scale bar represents 15 mm).
Ptenflx/flx;ROSAYFP E12.5 embryos generated large YFP+ tumors (F and G) that
ssion; high proliferation rate (K); and ultrastructural features (L andM) of human
intact (WT) alleles in normal tissue (N).
t were Cre-electroporated in utero.
PC; E12.5 and adult CPE (eCP and aCP); WNT and Sonic Hedgehog (SHH)
cerebellum (eCB); and E12.5 lower rhombic lip (eLRL).
ent score (NES) and the false discovery rate (FDR) Q value.
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Figure 2. Cross-Species Analysis of Syntenic Chromosomal Gains in Human and Mouse CPC
(A and B) Heatmaps of genomewide DNA copy number alterations in human CPPs and CPCs (A) and mouse CPCs (B).
(C–E) Heatmaps of the copy number of chromosome 1 (C), 7 (D), and 12 (E) in human CPPs and CPCs (left in each figure) and the corresponding syntenic regions
in mouse CPCs (right in each figure).
See also Tables S2, S3, S4, S5, S6, and S7.relatively high levels of RAD54L (Figure S1). Therefore, in light of
these data, we selected Taf12,Nfyc, andRad54l for further study
as potential CPC oncogenes.716 Cancer Cell 27, 712–727, May 11, 2015 ª2015 Elsevier Inc.Taf12, Nfyc, and Rad54l Maintain CPC
Next, we tested whether Taf12,Nfyc, and/or Rad54l are required
to maintain CPC cells both in vitro and in vivo. To ablate the
Figure 3. A Common Set of 21 Syntenic
Genes Gained and Overexpressed on
1p31.3-ter in Human and 4qC6-qE2 in
Mouse, CPC
Top: heat maps of human chromosome 1 copy
number in 34 human CPCs and CPPs (left), and
mouse chromosome 4qC6-qE2 in 27mouseCPCs
and normal choroid (right).
Middle: TP53 status and tissue type of each
sample.
Bottom: heat maps reporting the expression of 21
copy-number driven orthologs located on human
chromosome 1p31.3-ter in the 34 human tumors
(left) and 27 mouse CPCs and normal choroid
(right). Dotted lines demarcate the results of in-
dependent microarray probes for each human and
mouse ortholog. Gene symbols are shown on the
right.
See also Figure S1.expression of these candidate oncogenes, we generated three
shRNA-green fluorescence protein (GFP) lentiviruses against
each candidate. We also generated mismatch-control shRNAs
(controlshRNA) for Taf12, Nfyc, and Rad54l (one per candidate)
in which five bases of each shRNA sequence were mutated to
reduce target homology. Finally, shRNAs targeting two ‘‘control’’
genes (Pqlc2 andMier1) on chr1p31.3-ter/4qC6-qE2 that did not
induce dysplasia or aberrant proliferation of developing CPE
were also generated (Figure 5C).
Greater than 90%ofmouse primaryCPC cells were transduced
following exposure to lentiviruses in vitro, resulting in R50%
knockdown of the corresponding target gene relative to con-
trolshRNA transduced cells (Figure 6A). Ablation of either
Rad54lshRNAorTaf12shRNA inducedsignificantCaspase3/7activity
inmouse CPC cells and dramatically reduced the survival of these
cells in culture relative to controlshRNA, Pqlc2shRNA, or Mier1shRNA
transduced cells (Figures 6B and 6C). In contrast, knockdown of
Nfyc did not affect apoptosis or survival of CPC cells in vitro.
To test if Taf12, Nfyc, and Rad54l maintain CPC cells in vivo,
we transduced primary CPC cells with Taf12shRNA, NfycshRNA,
Rad54lshRNA, or controlshRNA and transplanted them orthotopi-
cally into the hindbrains of immunocompromised mice (Fig-
ure 6D). In agreement with our in vitro data, the median survival
of mice harboring Taf12shRNA (n = 6, median survival 34 days) or
Rad54lshRNA (n = 8, median survival 55.5 days) transduced CPC
cells was significantly longer thanmice injectedwith controlshRNA
transduced CPC cells (n = 19, median survival 19 days; p < 0.005
log rank; Figure 6D). Mice harboring NfycshRNA transduced CPCCancer Cell 27, 712–7cells also survived longer than control an-
imals (n = 5, median survival 29 days, p =
0.05 log rank). Thus, expression of Taf12,
Nfyc, and Rad54l appears to support
optimal growth of CPC cells, supporting
the notion that they are oncogenes.
Taf12, Nfyc, and Rad54l Are
Required to Initiate CPC
Because gain of 4qC6-qE2 coincided
with the onset of severe hyperplasia inour mouse model (Figure 4), we next tested whether the expres-
sion of our candidates is required to initiate CPC. Cre Recombi-
nase was electroporated into the hindbrain choroid plexus of
E12.5 Tp53flx/flx; Rbflx/flx; Ptenflx/flx; ROSAYFP mouse embryos
exactly as described above, but this time we simultaneously in-
jected the IV ventricle of these embryos with either Taf12shRNA
(n = 6 mice) NfycshRNA (n = 13 mice), Rad54lshRNA (n = 10 mice)
or controlshRNA (n = 12 mice) lentivirus. Remarkably, whereas
42% (n = 5/12) of Cre-electroporated mice injected with con-
trolshRNA developed CPCs, injection of either Taf12shRNA or
NfycshRNA lentiviruses completely abolished CPC development
and only 10% (n = 1/10) of mice receiving Rad54lshRNA lentivi-
ruses developed tumors (p < 0.05 log rank; Figure 6E). To
confirm that the choroid plexus of mice injected with active
shRNAs underwent Cre-recombination and viral transduction,
we reviewed the hindbrains of these animals after R100 days.
Several of these mice contained hyperplastic but histologically
benign choroid plexus masses containing numerous YFP+
(Cre-recombined) and GFP+ (shRNA transduced) cells (Fig-
ure 6F), suggesting that expression of shRNAs had arrested
CPC development. These data provide compelling evidence
that expression of Taf12, Nfyc, or Rad54l is critical for the initia-
tion of CPC.
Upregulation of Taf12, Nfyc, and Rad54l Drives CPC
Having shown that loss of Taf12, Nfyc, and Rad54l expression
markedly impairs CPC initiation and maintenance, we conducted
two sets of experiments to test whether overexpression of these27, May 11, 2015 ª2015 Elsevier Inc. 717
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Figure 4. Serial Analysis of Choroid Plexus Transformation in Mice
(A) In utero electroporation of the hindbrain choroid plexus of Tp53flx/flx; Rbflx/flx; Ptenflx/flx; ROSAYFP E12.5 embryos resulted in progressive expansion of YFP+
choroid plexus (top row, scale bar represents 50 mm) that displayed: dysplasia (second row, hematoxylin and eosin [H&E]; dotted line and arrows indicate
disruption of normal single layer epithelium; scale bar represents 10 mm); loss of Ttr expression (third row, in situ hybridization; scale bar represents 20 mm) and
increasing proliferation (fourth row, nuclear BrdU incorporation marked with arrows [note dotted line encompasses same region in P0 H&E stain]; scale bar
represents 10 mm); accumulation of DNA DSB (gH2ax stain marked with arrows; scale bar represents 10 mm); and gain of 4qC6-qE2 (note two separate FISH
probes used targeting Stmn1 and Cdca8 relative to control Baat at 4qB1).
(B–D) Graphs to the right report the quantification of BrdU incorporation (B), gH2ax stain (C), and gain of 4qC6-qE2 (D) in recombined (YFP+) cells. Error bars
represent mean ± SE. Mann Whitney, *p < 0.05, ***p < 0.0005.genes might promote disease initiation and/or progression. First,
we tested if IV ventricular co-injections of Taf12-cop(c)GFP,Nfyc-
cGFP, and Rad54l-cGFP expressing lentiviruses (1.673 105 len-
tiviral particles each per mouse, total = 5 3 105 particles) alters
CPC disease course in Cre-electroporated Tp53flx/flx; Rbflx/flx;718 Cancer Cell 27, 712–727, May 11, 2015 ª2015 Elsevier Inc.Ptenflx/flx; ROSAYFP E12.5 embryos. The tumor-free survival of
Cre-electroporated and lentivirus injected mice was significantly
reduced relative to that of mice that were Cre-electroporated
alone (Figure 7A; log rank p < 0.05). Mice that were injected
with Taf12-cGFP, Nfyc-cGFP, and Rad54l-cGFP lentiviruses but
BC
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Figure 5. Functional In Utero Assessment of 1p31.3-ter/4qC6-qE2 Candidate CPC Oncogenes
(A) E12.5 choroid plexus was co-electroporated with plasmids encoding candidate and GFP to identify electroporated cells. Gels below show seven examples of
21 reverse-transcriptase (RT) PCR results of cells transfected with control plasmid or oncogene candidates with or without RT.
(B) Sections from each animal were analyzed both for morphological change (top, H&E) and proliferation of electroporated cells (bottom, BrdU+/GFP+; scale bar
represents 10 mm). Only Taf12, Nfyc, and Rad54l demonstrated dysplasia and aberrant proliferation relative to the other 18 candidates, Pgd shown as an
example.
(C) Graph reporting the percentage of electroporated (GFP+) and proliferating choroid plexus epithelium cells. Error bars represent mean ± SE. *p < 0.05, **p <
0.005, Mann-Whitney.
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Figure 6. Taf12, Nfyc, and Rad54l Are Required to Initiate and Maintain CPC in Mice
(A) Reverse-transcriptase PCR of CPC cells transduced with control or gene targeted shRNA lentivirus.
(B) In vitro survival of CPC cells transduced with the indicated shRNA lentivirus. ***p < 0.0005, relative to controlshRNA cells. Error bars represent mean ± SE.
(C) Caspase 3/7 assays of control and shRNA-transduced CPC cells. Error bars represent mean ± SE. *p < 0.05, relative to controlshRNA cells.
(D) Kaplan-Meyer survival curves of mice implanted with CPC cells transduced with the indicated shRNA lentiviruses. *p < 0.05, **p < 0.005, ***p < 0.0005, Log-
Rank relative to controlshRNA mice.
(E) Kaplan-Meyer survival curves of Tp53flx/flx; Rbflx/flx; Ptenflx/flx; ROSAYFPmice electroporated at E12.5 with Cre-recombinase and simultaneously injected in the
hindbrain with the indicated shRNA (p < 0.05, log-rank comparison of the three survival curves).
(F) Morphology (H&E), lentiviral transduction (GFP), and Cre-recombination (RosaYFP) of hyperplastic choroid plexus mass in adult Tp53flx/flx; Rbflx/flx; Ptenflx/flx;
ROSAYFP mouse electroporated at E12.5 with Cre-recombinase and simultaneously injected in the hindbrain with Taf1shRNA (scale bar represents 20 mm).were not Cre-electroporated contained numerous cGFP+ CPE
cells but did not develop CPCs (total mice n = 7, median follow
up 374 days; Figure 7A). Thus, increased expression of Taf12,
Nfyc, and Rad54l significantly accelerates CPC development in
Tp53,Rb,Pten deletedCPE, but is not sufficient to initiate the dis-
ease. These data are compatible with the observation that 4qC6-
qE2 is gained following deletion of Tp53, Rb, Pten, but precedes
CPE transformation (Figures 4A and 4D).720 Cancer Cell 27, 712–727, May 11, 2015 ª2015 Elsevier Inc.As a further test of whether upregulation of Taf12, Nfyc, and
Rad54l can cooperate with TSG deletion to drive CPC, we gener-
ated a variant of our mouse model in which we titrated the
amount of Tp53, Rb, and Pten deletion using a Cre Recombi-
nase-cGFP (Cre-cGFP) lentivirus. In utero injection of 5.0 3 105
Cre-eGFP lentiviral particles into the IV ventricle of E12.5
Tp53flx/flx; Rbflx/flx; Ptenflx/flx; ROSAYFP mice resulted in highly
penetrant YFP+ (recombined) cGFP+ (lentiviral transduced)
CPCs (86%, n = 6/7; Figures 7B and 7C). In contrast, injection of
just 1.25 3 105 Cre-cGFP lentiviral particles yielded no tumors;
although these mice did retain YFP+/cGFP+ co-expressing
CPE cells and some developed hindbrain choroid plexus hyper-
plasia (n = 8, median follow up 381 days; Figures 7B and 7C).
Thus, lentiviral delivery of Cre-recombinase serves as a titratable
alternate to electroporation for inducing CPCs in our model
system.
Because 1.253x 105 Cre-cGFP viral particles failed to
generate CPCs in E12.5 Tp53flx/flx; Rbflx/flx; Ptenflx/flx; ROSAYFP
mouse embryos, we tested if concurrent delivery of Taf12-
cGFP, Nfyc-cGFP, and Rad54l-cGFP lentiviruses might coop-
erate with this level of recombination to promote tumorigenesis.
Seventy-five percent (n = 9/12) of E12.5 Tp53flx/flx; Rbflx/flx;
Ptenflx/flx; ROSAYFP mouse embryos injected with 1.25x105
Cre-eGFP lentiviral particles and an equal mix of Taf12-cGFP,
Nfyc-cGFP, and Rad54l-cGFP (3.75 3 105 particles) developed
YFP+/cGFP+ CPCs (total viral particles 5.03 105 permouse; Fig-
ures 7B and 7C). In situ hybridization and immunofluorescence
analysis of these tumors confirmed high-level co-expression of
Taf12, Nfyc, and Rad54l (Figure 7E). To control for the possibility
that high viral titers (53 105 particles) are non-specifically trans-
forming, we repeated our experiments but this time co-injected
1.253 105Cre-cGFP lentiviral particles with 3.753 105 particles
of a single candidate (Taf12-cGFP, total viral particles 5 3 105
per mouse). These mice also developed CPC, but at a signifi-
cantly lower penetrance than animals receiving all three onco-
gene candidates (22%, n = 2/9; Figure 7C). Similar experiments
showed that Taf12, Nfyc, and Rad54l can also drive CPC in
postnatal choroid plexus (Figure 7D). Together with our cross-
species genomic and in vivo gene knockdown studies, these
data comprehensively validate Taf12, Nfyc, and Rad54l as
CPC oncogenes and support the notion that concurrent gain of
these three genes on chr1p31.3-ter/4qC6-qE2 cooperates with
deletion of Tp53, Rb, and Pten in the initiation and progression
of CPC.
Aberrant DNA Metabolism Is a Significant Feature
of CPC
TAF12, NFYC and RAD54L are key regulators of DNA meta-
bolism, suggesting that dysregulation of DNA maintenance
and/or repair are necessary for CPC formation (Benatti et al.,
2011; Nardini et al., 2013; Schmitz et al., 2009;Wright andHeyer,
2014). As a first step to test this, we used GSEA to compare the
transcriptomes of mouse E12.5 CPE with those of daughter
CPCs, andmeasured the sensitivity of CPC cells to two separate
inhibitors of the ataxia telangiectasia and Rad3-related protein
(ATR) kinase that regulates DNA repair, including DSBs (Somyajit
et al., 2013). In keeping with our hypothesis, numerous gene sets
that maintain the integrity of the genome and epigenome were
significantly upregulated in CPC (Figures 8A and 8B; Table S1).
As expected, Rad54l was the most upregulated homologous
repair gene (Figure 8B). Notably, DNA replication and repair
gene sets were also enriched in human CPCs that are diploid
for chromosome 1, suggesting dysregulation of these cell func-
tions are a general feature of CPC (Table S8).
Finally, CPC cells proved remarkably sensitive to ATR inhibi-
tors in vitro relative to cells from an unrelated mouse brain tumor
model of ependymoma (Figure 8C). Exposure of CPC cells to0.4 mM AZ-20 that inhibited their growth by 90%, increased the
induction of DNA DSB in these cells >3-fold after only 6 hours;
however, this concentration of AZ-20 had no impact on ependy-
moma cell proliferation or DSB formation (Figures 8C and 8D).
Importantly, although sensitivity to ATR inhibitors may vary
with basal levels of replicative stress; CPC cells proliferated
slightly slower that ependymoma cells (doubling time 25.7 hr ±
1.2SD CPC versus 19.6 hr ± 1.7SD ependymoma) and no signif-
icant difference in replication stress was detected between un-
treated CPC and ependymoma cells (Figure 8D). These data
support the hypothesis that gain of TAF12, NFYC, and RAD54L
on chr1p31.3-ter/4qC6-qE2 promotes aberrant DNA mainte-
nance and repair during CPC formation and suggest that inhibi-
tion of this activity may have therapeutic potential.
DISCUSSION
Using a combination of cross-species genomics and in vivo
mouse modeling, we describe a mouse model of CPC; demon-
strate that postnatal CPE from which TSGs have been deleted
in utero can generate these tumors; identify three oncogenes—
TAF12, NFYC, and RAD54L—that are required to initiate and
maintain the disease; and implicate upregulation of DNAmainte-
nance and repair as a critical requirement for CPC formation.
How might concurrent gain of TAF12, NFYC, and RAD54L
contribute to CPC formation? Both TAF12 and NFYC are his-
tone-fold domain containing transcription factors (Bieniossek
et al., 2013; Nardini et al., 2013). TAF12 recruits GADD45, and
thereby the nucleotide excision repair machinery, to the pro-
moter of active genes, removingmethylated cytosines andmain-
taining a hypomethylated active state (Schmitz et al., 2009).
Transcriptional regulation by TAF12 is thought to contribute to
transformation, possibly by promoting an invasive phenotype
(Voulgari et al., 2008). NFYC is also engaged in chromatin re-
modeling, establishing permissive chromatin modifications at
CCAAT promoters, including those of cell cycle regulators (Be-
natti et al., 2011; Nardini et al., 2013). Deletion of NFYC or the
related gene NFYB, halts cell cycle progression, predominantly
by causing a G2/M arrest (Benatti et al., 2011). Thus, upregula-
tion of TAF12 and NFYC might promote an aberrant epigenome
during CPE transformation, maintaining or re-activating the
expression of proto-oncogenes that are normally silenced in
post-mitotic, postnatal choroid plexus. This notion is supported
by our observation that the CPC transcriptome most closely
matches embryonic CPE. RAD54L plays a central role in homol-
ogous recombination in which damaged DNA—particularly
DSBs—are repaired by copying an intact homologous sequence
(Wright and Heyer, 2014). Loss of Rad54l from Tp53 and LigIV
null cells results in the accumulation of DSBs, severe chromo-
somal defects, and failed cell proliferation (Mills et al., 2004).
Therefore, upregulation of RAD54L may be required for CPE to
tolerate the severe genotoxic stress that is associated with
rampant proliferation in the context of accumulating chromo-
somal insults. Our observations that Tp53/Rb/Pten null CPE
accumulate DSBs that apparently resolve following the gain of
4qC6-qE2, and that CPC transcriptomes are markedly enriched
for DNA repair genes, supports this concept.
In light of our data, we propose a hypothesis for the develop-
ment of CPC; particularly in patients with germline mutations inCancer Cell 27, 712–727, May 11, 2015 ª2015 Elsevier Inc. 721
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Figure 7. Taf12, Nfyc, and Rad54l Expression Promote CPC in Mice
(A) Kaplan-Meyer survival curves of Tp53flx/flx; Rbflx/flx; Ptenflx/flx ; ROSAYFP mice injected in the hindbrain at E12.5 with Taf12-, Nfyc-, and Rad54l-ex-
pressing lentiviruses following sham (no Cre) or Cre-electroporation (Cre). Survival of Cre-electroporated mice not receiving lentivirus is also shown
(Cre only).
(legend continued on next page)
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TP53 (Figure 8E). We propose that the loss of TP53 (and poten-
tially RB and PTEN) from CPE results in the accumulation of ge-
netic and epigenetic changes that disrupt terminal differentiation
and senescence. Early in postnatal life, these aberrantly prolifer-
ating CPE cells develop increasingly abnormal genomes leading
to genotoxic crisis. While most of these cells undergo cell death,
presumably through TP53-independent mechanisms, a fraction
acquire aberrant DNA repair and epigenome remodelling capac-
ity, including gain of TAF12, NFYC, and RAD54L. This enables
them to tolerate an aberrant but stable genome and drive further
transformation. The advantage afforded by these genes pro-
vides a selective pressure for retention of chr1p31.3-ter/4qC6-
qE2 gain. These mutant CPE cells go on to form CPCs that
can tolerate the recurrent and extensive chromosome changes
associated with the disease. Thus, the concurrent gain of
TAF12, NFYC, and RAD54Lmay serve to model an aberrant epi-
genome that promotes a proliferative, and relatively undifferenti-
ated state (TAF12 and NFYC) while tolerating genotoxic stress
(RAD54L). Interestingly, recent data indicate that CPCs that do
not gain chromosome 1 retain both copies of this chromosome
in an otherwise hypodiploid genome (Merino et al., 2014).
Thus, absolute or relative gain of this chromosome might be
required for CPC development.
Our demonstration that increased expression of Taf12, Nfyc,
and Rad54l induce dysplasia and aberrant proliferation in other-
wise wild-type CPE, support the notion that these are CPC
oncogenes. However, the dependency of transforming cells
on aberrant DNA repair may also occur in the context of non-
oncogene addiction (Luo et al., 2009). Thus, CPCs might be
‘‘addicted’’ to RAD54L, and/or the targets of TAF12 and NFYC
chromatin remodelling, as non-oncogenes. Regardless of the
underlying mechanism, validation of aberrant DNA repair as a
requirement for CPC formation and maintence could lead to
new therapies, because inhibition of DNA repair enzymes
should result in intolerable DNA damage. Precedent for this
approach exists in the addiction of BRCA2 mutant cells to the
DNA repair enzyme PARP1 and our demonstration that CPC
cells are sensitive to ATR inhibitors (Sakai et al., 2008). As well
as suggesting potential drug targets within DNA repair path-
ways, our data show that inhibitors of phosphatidylinositol-
4,5-bisphosphate 3-kinase (PI3K) signaling (suppressed by
PTEN) might also serve as new CPC treatments. However,
translating these and other potential new therapies to the clinic
for CPC has proved immensely challenging since fewer than 50
children are diagnosed with this disease in the United States
each year (CBTRUS, 2006; Paulus and Brandner, 2007). There-
fore, rigorous preclinical studies using our faithful model of CPC
could help discover, triage and prioritize potential new therapies
for clinical trial.
Our model also provides a useful system to study the origin of
CPC. There are at least two candidate cells of origin of CPC: CPE
progenitors located near the anterior lower rhombic lip (Awatra-(B) Left: macroscopic, direct YFP fluorescence of the hindbrains of adult Tp53flx/flx
lentivirus at E12.5. Right: images of H&E-stained or immunofluorescence-stained
(C andD) Kaplan-Meyer survival curves of Tp53flx/flx;Rbflx/flx;Ptenflx/flx;ROSAYFPm
Statistics report the log-rank comparison of the survival curves.
(E) In situ hybridization (top andmiddle) and immunofluorescence (bottom) of Taf1
bars represent 50 mm.mani et al., 2003; Currle et al., 2005; Huang et al., 2009; Hunter
and Dymecki, 2007; Lehtinen et al., 2013) and fully differentiated,
post-mitotic, Ttr+ progeny that populate the CPE. Our serial his-
tologic review of Cre-recombined CPE revealed multiple sto-
chastic regions of proliferative and dysplastic CPE sandwiched
between otherwise normal regions of mature CPE, favoring
mature, post-mitotic CPE as the origin of tumors.
Finally, our syntenicmapping approach holds promise to iden-
tify oncogenes located within large regions of chromosomal gain
in other cancers. Indeed, emerging evidence suggests that large
CNAs characteristic of other pediatric solid tumors are replicated
when these tumors develop in other species (Chen et al., 2013;
Frappart et al., 2009). Similar studies of syntenic regions of
loss coupled with RNA silencing technologies could be applied
to discover TSGs (Scuoppo et al., 2012; Xue et al., 2012; Zender
et al., 2008).
EXPERIMENTAL PROCEDURES
Mouse Tumorigenesis Studies
All in vivo experiments were performed in accordance with protocols that were
reviewed and approved by the St. Jude Children’s Research Hospital Animal
Care and Usage Committee. Mice harboring conditional floxed alleles of
Tp53, Rb, Pten, and ROSAYFP (Chow et al., 2011) were housed and studied
under St. Jude IACUC approved protocols. The choroid plexuses of E12.5
mouse embryos were electroporated in utero using pcDNA3.1 plasmids en-
coding Cre-Recombinase, GFP, and/or candidate oncogenes exactly as we
described previously (Gibson et al., 2010). Electroporation was performed us-
ing a CUY-21 electroporator (Nepa Gene Do.) with five 50-ms pulses of 50 V
with 950-ms intervals. Actively proliferating CPE and CPC cells were labeled
in vivo by injection of 0.1mg/kg bromodeoxyuridine (BrdU, Sigma-Aldrich) 2
hours prior to killing the animals. Lentiviruses encoding the cDNA of Cre-
Recombinase, Taf12, Rad54l, or Nfyc, or shRNAs targeting these genes (three
shRNAs per gene designed using http://dharmacon.gelifesciences.com) were
cloned into lentiviruses, packaged, titrated and injected in utero into the em-
bryonic IV ventricle exactly as we described previously (Robinson et al.,
2012). Mismatch control shRNAswere generated bymutating five baseswithin
the 21-mer sequence of each shRNA. Orthotopic implants of CPCs were
generated by injecting the hindbrains of 5- to 6-week-old female CD1 nude
mice (http://www.criver.com) with 5 3 106 CPC cells transduced with control
or shRNA-lentivirus suspended in 10 ml Matrigel. CPC cells were injected into
IV ventricle through cisterna magna using Hamilton syringe.
Immunohistochemistry and In Situ Hybridization
Formalin fixedandparaffinembeddedmouseCPCs (or forATR inhibitor studies,
cytospins of culturedCPCcells)were stainedwith standard immunohistochem-
ical approaches using rabbit polyclonal antibodies to Ki67 (Vector Labs), Phos-
pho-HistoneH2A.XSer139 (Cell signaling),GFP (Invitrogen), copGFP (Evrogen); or
mouse monoclonal antibodies to BrdU (Sigma-Aldrich), Taf12, Nfyc, or Rad54l
(Abcam). For immunofluorescence staining, second antibodies were conju-
gatedwith either Alexa488 or Alexa 594 and sectionsmountedwith Vectashield
mounting medium containing DAPI (Vector Laboratories).
In situ hybridization (ISH) was performed using standard approaches
and probes generated using the open reading frames of Taf12 (cDNA clone
MGC:30438 IMAGE:3493047), Nfyc (cDNA clone MGC:28940 IMAGE:
4009737),Rad54l (cDNAcloneMGC:13963 IMAGE:3987790), andTtr (generous
gift of Dr. EdwinMonuki, IMAGEclone 1078224, accessionNumber AA822938).;Rbflx/flx;Ptenflx/flx;ROSAYFPmice receiving hindbrain injections of the indicated
sections of the corresponding hindbrain, left (scale bars represent 50 mm).
ice injected in the hindbrain at E12.5 (C) or P1 (D) with the indicated lentiviruses.
2,Nfyc, and Rad54l expression in CPCs induced by lentiviral injection. All scale
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Figure 8. DNA Repair Is Upregulated in CPC
(A) GSEA of ‘‘Kauffmann DNA Repair Gene’’ set in CPC versus E12.5 CPE.
(B) Heat map reporting the GSEA of the ‘‘Kegg Homologous Repair Gene’’ set in CPC versus E12.5 CPE.
(C) Growth inhibition assays of mouse CPC and ependymoma (Johnson et al., 2010) cells following 72 hr exposure to the ATR inhibitors AZ-20 and VE-821. Error
bars represent mean ± SE.
(D) Quantification of DNADSBs in the CPC and ependymoma cells shown in C, both before (time 0) and at the indicated times following exposure to 0.4 mMAZ-20.
Error bars represent mean ± SE.
See also Table S8.
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Dual-color fluorescence in situ hybridization (FISH) to estimate DNA copy
number was performed on 5 mm paraffin-embedded tissue sections with
BAC clones encoding Baat, Cdca8, and Stmn1 (BACPAC Resources). Probes
were labeled with either AlexaFluor-488 or AlexaFluor-555 fluorochromes and
nuclei were counterstained with DAPI (Vector Laboratories).
RNA and DNA Microarray Analysis
Human CPCs and CPPs and associated clinical data were collected from in-
stitutions in Canada, USA, Brazil, Israel, and Germany in accordance with
each institution’s Research Ethics Board. Informed consent was obtained
from the parents/legal guardians of all patients. In addition, the research con-
ducted using these samples was reviewed by St. Jude Children’s Research
Hospital Institutional Review Board and/or were appropriate the Hospital for
Sick Children’s Research Ethics Board. DNA was isolated from both human
and mouse tumors and tissues using standard phenol-chloroform. RNA was
isolated using TRIzol (Invitrogen). Gene expression profiles of human and
mouse RNAs were generated using GeneChip Human Exon 1.0ST and
430v2 microarrays, respectively (Affymetrix). Gene expression data were
normalized and analyzed to detected significantly differentially expressed
genes exactly as described previously (Parker et al., 2014).
Human and mouse DNA samples were hybridized to Genome-Wide Human
SNP Array 6.0 (Affymetrix) and the Mouse Genome CGH 244K (Agilent),
respectively. Human gene copy number was inferred using Partek Genomics
Suite 6.5 and genomic segmentation algorithm (Partek). Segmented regions
were those significantly different from neighboring regions (p < 0.001) and
contained 10 or more probes, with a signal to noise ratio of 0.3. Mouse
aCGH tumor data were compared to a common control as reference DNA
and the circular binary segmentation algorithm [1] implemented in the
DNAcopy package from Bioconductor used to identify copy number alter-
ations for each tumor sample. Aberrant segments contained at least five
probes with a mean log2 ratio greater than 0.3 or less than 0.3.
Whole Genome Sequencing Data Analysis
Detection of somatic single nucleotide variations (SNVs), indels, structural var-
iations and focal copy number changes from whole genome sequencing
(WGS) was performed as previously described and are described in detail in
the Supplemental Experimental Procedures (Parker et al., 2014).
Cell Culture
Fresh, primary, CPC tumor tissue was dissected from the IV ventricle of mice,
minced and disaggregated using hyaluronidase (Atlanta Biologicals) and colla-
genase type IV (Invitrogen). Disaggregated cells were filtered through a 40 mm
cell strainer and transduced with control or shRNA-lentiviruses. The prolifera-
tion of single cell suspensions cultured in neurobasal medium, in the presence
or absence of the indicated concentration of ATR inhibitors was recorded
usingCellTiter-Glo as described (Gibson et al., 2010). Apoptosis was assessed
in single cell suspensions using the CaspaseGlo assay (see Supplemental
Experimental Procedures).
Quantitative Reverse Transcriptase PCR
Total cDNA was generated from cells and analyzed using qRT-PCR and stan-
dard approaches. Primers pairs used in assays included TAF12 (AGCCATCT
CATCCTTGGATTTTT: ACGACCAAAATGCTCTTCCTACA), NFYC (AGGAC
AGATCCAGACACTTGCTAC: GATTGGCTGACTGAATAAACATGG), Rad54l
(CCTGGTGAAGAACTGGTACAATG: ATGACCAGTCCAACATTTCCTTT) and
Gapdh (AGGTCGGTGTGAACGGATTTG: TGTAGACCATGTAGTTGAGGTCA).
ACCESSION NUMBERS
The accession number for the WGS data reported in this paper is European
Bioinformatics Institute EGAS00001000961. Human and mouse RNA and
DNA microarray data are available from GEO (GSE60899).
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